This is the authors' abstract. We don't add key points for this paper.
Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH management and research.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: